These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 12551928)
1. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. Snyder H; Mensah K; Theisler C; Lee J; Matouschek A; Wolozin B J Biol Chem; 2003 Apr; 278(14):11753-9. PubMed ID: 12551928 [TBL] [Abstract][Full Text] [Related]
2. beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein. Snyder H; Mensah K; Hsu C; Hashimoto M; Surgucheva IG; Festoff B; Surguchov A; Masliah E; Matouschek A; Wolozin B J Biol Chem; 2005 Mar; 280(9):7562-9. PubMed ID: 15591046 [TBL] [Abstract][Full Text] [Related]
3. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. Tofaris GK; Layfield R; Spillantini MG FEBS Lett; 2001 Nov; 509(1):22-6. PubMed ID: 11734199 [TBL] [Abstract][Full Text] [Related]
4. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Petrucelli L; O'Farrell C; Lockhart PJ; Baptista M; Kehoe K; Vink L; Choi P; Wolozin B; Farrer M; Hardy J; Cookson MR Neuron; 2002 Dec; 36(6):1007-19. PubMed ID: 12495618 [TBL] [Abstract][Full Text] [Related]
5. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. Stefanis L; Larsen KE; Rideout HJ; Sulzer D; Greene LA J Neurosci; 2001 Dec; 21(24):9549-60. PubMed ID: 11739566 [TBL] [Abstract][Full Text] [Related]
6. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Rideout HJ; Stefanis L Mol Cell Neurosci; 2002 Oct; 21(2):223-38. PubMed ID: 12401444 [TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Ancolio K; Alves da Costa C; Uéda K; Checler F Neurosci Lett; 2000 May; 285(2):79-82. PubMed ID: 10793231 [TBL] [Abstract][Full Text] [Related]
8. Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival. Lee G; Junn E; Tanaka M; Kim YM; Mouradian MM J Neurochem; 2002 Oct; 83(2):346-52. PubMed ID: 12423244 [TBL] [Abstract][Full Text] [Related]
9. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. Rideout HJ; Larsen KE; Sulzer D; Stefanis L J Neurochem; 2001 Aug; 78(4):899-908. PubMed ID: 11520910 [TBL] [Abstract][Full Text] [Related]
12. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595 [TBL] [Abstract][Full Text] [Related]
13. Pathological proteins in Parkinson's disease: focus on the proteasome. Snyder H; Wolozin B J Mol Neurosci; 2004; 24(3):425-42. PubMed ID: 15655264 [TBL] [Abstract][Full Text] [Related]
14. [Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease]. Corti O; Brice A J Soc Biol; 2002; 196(1):95-10. PubMed ID: 12134640 [TBL] [Abstract][Full Text] [Related]
15. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. Tofaris GK; Razzaq A; Ghetti B; Lilley KS; Spillantini MG J Biol Chem; 2003 Nov; 278(45):44405-11. PubMed ID: 12923179 [TBL] [Abstract][Full Text] [Related]